<p>根据斯堪的纳维亚银行（Skandinaviska Enskilda Banken AB publ）最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第三季度将其在 Summit Therapeutics PLC（NASDAQ:SMMT - 免费报告）中的持股增加了 409.2%。该公司在本季度额外购买了 271,912 股后，持有 338,363 股该公司的股票。斯堪的纳维亚银行在 Summit Therapeutics 的持股在最近一个季度末的价值为 6,991,000 美元。</p>
<p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<ul>
<li>为什么华尔街支持这三只复苏股票</li>
</ul>
<p>其他机构投资者也对该公司的持股进行了调整。Crowley Wealth Management Inc.在第三季度将其在 Summit Therapeutics 的持股增加了 66.7%。Crowley Wealth Management Inc.现在拥有 1,500 股该公司的股票，价值 31,000 美元，此前在上个季度又购买了 600 股。SBI Securities Co. Ltd.在第二季度将其在 Summit Therapeutics 的持股增加了 34.1%。SBI Securities Co. Ltd.现在拥有 1,756 股该公司的股票，价值 37,000 美元，此前在此期间又购买了 447 股。PNC Financial Services Group Inc.在第二季度将其在 Summit Therapeutics 的持股增加了 325.5%。PNC Financial Services Group Inc.现在拥有 2,638 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,018 股。SG Americas Securities LLC 在第三季度获得了 Summit Therapeutics 的新股份，价值 106,000 美元。最后，AlphaQuest LLC 在第二季度将其在 Summit Therapeutics 的持股增加了 131.7%。AlphaQuest LLC 现在拥有 5,891 股该公司的股票，价值 125,000 美元，此前在此期间又购买了 3,349 股。4.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Summit Therapeutics 股票表现</h2>
<p>NASDAQ:SMMT 周五开盘价为 15.87 美元。该公司的市值为 122.4 亿美元，市盈率为-12.80，贝塔值为-1.44。该股票的 50 日移动平均价格为 16.67 美元，200 日移动平均价格为 19.50 美元。Summit Therapeutics PLC 的 52 周最低价为 13.83 美元，52 周最高价为 36.91 美元。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
<p>几位股票研究分析师最近对该公司发布了报告。Piper Sandler 在 1 月 14 日的研究报告中将 Summit Therapeutics 的目标价设定为 40.00 美元。Zacks Research 在 2 月 4 日的报告中将 Summit Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。巴克莱在 12 月 17 日的报告中将 Summit Therapeutics 的评级从 “减持” 上调至 “持平”，并将其目标价从 16.00 美元提高至 18.00 美元。花旗在 1 月 30 日的研究报告中重申了对 Summit Therapeutics 的 “市场表现优于大盘” 评级。最后，HC Wainwright 在 2 月 2 日的研究报告中重申了 “买入” 评级，并对 Summit Therapeutics 的目标价设定为 40.00 美元。一位研究分析师对该股票给予了强烈买入评级，九位给予了买入评级，三位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 33.08 美元。</p>
<p><strong>查看我们对 Summit Therapeutics 的最新股票分析</strong></p>
<h2>关于 Summit Therapeutics</h2>
<p>（免费报告）</p>
<ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则的改变者吗？</li>
</ul>
<p>Summit Therapeutics plc 是一家临床阶段的生物技术公司，致力于为严重和危及生命的疾病发现和开发精准医疗。该公司采用针对性的药物设计方法，专注于与现有疗法不同的新机制。</p>
<p>Summit 的主要资产，ridinilazole（前称 SMT19969），正在开发用于治疗艰难梭菌感染，并已获得美国的快速通道和合格感染性疾病产品认证。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票比 Summit Therapeutics 更好</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
<p>在考虑投资 Summit Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Summit Therapeutics 并不在名单上。</p>
<p>虽然 Summit Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做空 - Direxion

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

Summit治疗

医药突破 ETF - ALPS

<p>斯堪的纳维亚银行（Skandinaviska Enskilda Banken AB publ）在第三季度将其在 Summit Therapeutics PLC 的持股增加了 409.2%，目前持有 338,363 股，价值为 699 万美元。其他机构投资者也增加了他们的持股，Crowley Wealth Management 增加了 66.7%，PNC Financial Services 增加了 325.5%。Summit Therapeutics 的市值为 122.4 亿美元，市盈率为-12.80。分析师的评级意见不一，普遍评级为 “适度买入”，平均目标价为 33.08 美元</p>

<p>Skandinaviska Enskilda Banken AB publ grew its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 409.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 338,363 shares of the company's stock after buying an additional 271,912 shares during the quarter. Skandinaviska Enskilda Banken AB publ's holdings in Summit Therapeutics were worth $6,991,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根据斯堪的纳维亚银行（Skandinaviska Enskilda Banken AB publ）最近向证券交易委员会（SEC）提交的 13F 表格，该公司在 2023 年第三季度将其在 Summit Therapeutics PLC（NASDAQ:SMMT - 免费报告）中的持股增加了 409.2%。该公司在本季度额外购买了 271,912 股后，持有 338,363 股该公司的股票。斯堪的纳维亚银行在 Summit Therapeutics 的持股在最近一个季度末的价值为 6,991,000 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Why Wall Street Is Backing These 3 Comeback Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么华尔街支持这三只复苏股票</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. Crowley Wealth Management Inc. lifted its position in shares of Summit Therapeutics by 66.7% in the 3rd quarter. Crowley Wealth Management Inc. now owns 1,500 shares of the company's stock valued at $31,000 after acquiring an additional 600 shares in the last quarter. SBI Securities Co. Ltd. raised its stake in Summit Therapeutics by 34.1% during the 2nd quarter. SBI Securities Co. Ltd. now owns 1,756 shares of the company's stock valued at $37,000 after purchasing an additional 447 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Summit Therapeutics by 325.5% in the second quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $56,000 after purchasing an additional 2,018 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Summit Therapeutics in the third quarter worth $106,000. Finally, AlphaQuest LLC boosted its position in shares of Summit Therapeutics by 131.7% in the second quarter. AlphaQuest LLC now owns 5,891 shares of the company's stock worth $125,000 after buying an additional 3,349 shares during the period. 4.61% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的持股进行了调整。Crowley Wealth Management Inc.在第三季度将其在 Summit Therapeutics 的持股增加了 66.7%。Crowley Wealth Management Inc.现在拥有 1,500 股该公司的股票，价值 31,000 美元，此前在上个季度又购买了 600 股。SBI Securities Co. Ltd.在第二季度将其在 Summit Therapeutics 的持股增加了 34.1%。SBI Securities Co. Ltd.现在拥有 1,756 股该公司的股票，价值 37,000 美元，此前在此期间又购买了 447 股。PNC Financial Services Group Inc.在第二季度将其在 Summit Therapeutics 的持股增加了 325.5%。PNC Financial Services Group Inc.现在拥有 2,638 股该公司的股票，价值 56,000 美元，此前在上个季度又购买了 2,018 股。SG Americas Securities LLC 在第三季度获得了 Summit Therapeutics 的新股份，价值 106,000 美元。最后，AlphaQuest LLC 在第二季度将其在 Summit Therapeutics 的持股增加了 131.7%。AlphaQuest LLC 现在拥有 5,891 股该公司的股票，价值 125,000 美元，此前在此期间又购买了 3,349 股。4.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表现</h2>
</div><p>NASDAQ:SMMT opened at $15.87 on Friday. The company has a market capitalization of $12.24 billion, a P/E ratio of -12.80 and a beta of -1.44. The stock's 50 day moving average price is $16.67 and its 200 day moving average price is $19.50. Summit Therapeutics PLC has a 52 week low of $13.83 and a 52 week high of $36.91.</p>
<div class="lb-trans"><p>NASDAQ:SMMT 周五开盘价为 15.87 美元。该公司的市值为 122.4 亿美元，市盈率为-12.80，贝塔值为-1.44。该股票的 50 日移动平均价格为 16.67 美元，200 日移动平均价格为 19.50 美元。Summit Therapeutics PLC 的 52 周最低价为 13.83 美元，52 周最高价为 36.91 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 11/4 - 11/8</li>
</ul>
</div><p>Several equities research analysts recently issued reports on the company. Piper Sandler set a $40.00 price objective on Summit Therapeutics in a research note on Wednesday, January 14th. Zacks Research downgraded Summit Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a report on Wednesday, February 4th. Barclays upgraded shares of Summit Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and raised their price target for the stock from $16.00 to $18.00 in a report on Wednesday, December 17th. Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of Summit Therapeutics in a research report on Friday, January 30th. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $40.00 target price on shares of Summit Therapeutics in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $33.08.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发布了报告。Piper Sandler 在 1 月 14 日的研究报告中将 Summit Therapeutics 的目标价设定为 40.00 美元。Zacks Research 在 2 月 4 日的报告中将 Summit Therapeutics 的评级从 “持有” 下调至 “强烈卖出”。巴克莱在 12 月 17 日的报告中将 Summit Therapeutics 的评级从 “减持” 上调至 “持平”，并将其目标价从 16.00 美元提高至 18.00 美元。花旗在 1 月 30 日的研究报告中重申了对 Summit Therapeutics 的 “市场表现优于大盘” 评级。最后，HC Wainwright 在 2 月 2 日的研究报告中重申了 “买入” 评级，并对 Summit Therapeutics 的目标价设定为 40.00 美元。一位研究分析师对该股票给予了强烈买入评级，九位给予了买入评级，三位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 33.08 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Summit Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Summit Therapeutics 的最新股票分析</strong></p>
</div><h2>About Summit Therapeutics</h2>
<div class="lb-trans"><h2>关于 Summit Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他们的肺癌药物是游戏规则的改变者吗？</li>
</ul>
</div><p>Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.</p>
<div class="lb-trans"><p>Summit Therapeutics plc 是一家临床阶段的生物技术公司，致力于为严重和危及生命的疾病发现和开发精准医疗。该公司采用针对性的药物设计方法，专注于与现有疗法不同的新机制。</p>
</div><p>Summit's lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.</p>
<div class="lb-trans"><p>Summit 的主要资产，ridinilazole（前称 SMT19969），正在开发用于治疗艰难梭菌感染，并已获得美国的快速通道和合格感染性疾病产品认证。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>My Epstein Story</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Summit Therapeutics 更好</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>我的爱泼斯坦故事</li>
<li>这只 15 美元的股票可能会成为 2026 年的第一只股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U01NVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=SMMT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Summit Therapeutics 吗？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Summit Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Summit Therapeutics 并不在名单上。</p>
</div><p>While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Summit Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Skandinaviska Enskilda Banken AB publ 持有 Summit 治疗公司价值 699 万美元的股份